0
0

BENEFIT Act of 2020

2/9/2022, 3:11 AM

Congressional Summary of S 3385

Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2020 or the BENEFIT Act of 2020

This bill requires the Food and Drug Administration (FDA) to consider relevant patient-focused drug development data, such as data from patient preference studies and patient-reported outcome data, in the risk-benefit assessment framework used in the process for approving new drugs.

After a new drug application has been approved, the FDA's public statement about how it used patient experience data shall include a description of how such data was considered in the risk-benefit assessment framework.

Current Status of Bill S 3385

Bill S 3385 is currently in the status of Bill Introduced since March 4, 2020. Bill S 3385 was introduced during Congress 116 and was introduced to the Senate on March 4, 2020.  Bill S 3385's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of March 4, 2020

Bipartisan Support of Bill S 3385

Total Number of Sponsors
1
Democrat Sponsors
0
Republican Sponsors
1
Unaffiliated Sponsors
0
Total Number of Cosponsors
1
Democrat Cosponsors
1
Republican Cosponsors
0
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill S 3385

Primary Policy Focus

Health

Potential Impact Areas

- Drug safety, medical device, and laboratory regulation
- Health information and medical records
- Product development and innovation

Alternate Title(s) of Bill S 3385

BENEFIT Act of 2020
BENEFIT Act of 2020
Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2020
A bill to strengthen the use of patient-experience data within the benefit-risk framework for approval of new drugs.

Comments